Status:
TERMINATED
Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Hyperuricemia
Chronic Kidney Diseases
Eligibility:
All Genders
2-20 years
Phase:
PHASE2
Brief Summary
Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia...
Detailed Description
Uric acid levels often rise when kidney function declines. Historically, high uric acid has not been treated unless the uric acid crystallizes in the joint space and causes clinical gout disease, more...
Eligibility Criteria
Inclusion
- Chronic Kidney Disease stage 1-5
- Hyperuricemic (UA \>= 5.5 mg/dL)
Exclusion
- Contraindication to Allopurinol
- Elevated baseline liver function tests
- Receiving acute or chronic dialysis
- Primary metabolic disorder
- Sickle cell disease
- Autosomal Dominant Polycystic Kidney Disease
- Cystinosis
- Bartter or Gitelman Disease
- Pregnant or nursing
Key Trial Info
Start Date :
March 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03865407
Start Date
March 10 2019
End Date
October 7 2020
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298